Corvus Pharmaceuticals Inc Stock
Heavy losses for Corvus Pharmaceuticals Inc today as the stock fell by -€1.460 (-8.490%).
With 9 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 21 € shows a positive potential of 33.42% compared to the current price of 15.74 € for Corvus Pharmaceuticals Inc.
For the coming years our community has positive and negative things to say abot the Corvus Pharmaceuticals Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | -8.490% | - | 180.071% | 225.207% | 154.281% | 2062.385% | 442.759% |
| Heron Therapeutics Inc. | 4.460% | -8.380% | -23.686% | -42.083% | -12.657% | -60.567% | -93.571% |
| Madrigal Pharmaceuticals inc. | -2.110% | -3.244% | -7.832% | 16.141% | -21.625% | 62.792% | 286.640% |
| Biocryst Pharmaceuticals | 1.050% | 5.823% | -1.485% | -32.281% | -12.965% | -40.457% | -27.790% |
Comments
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $32.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for CRVS provided by MarketBeat
News
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic
